Enjaymo (sutimlimab) rapidly stopped hemolysis — destruction of red blood cells — while anti-cancer treatment targeted the underlying blood cancer believed to be driving secondary cold agglutinin disease (CAD) in a 61-year-old woman. This case “adds to the growing evidence that using short-term [Enjaymo] for [secondary CAD] as…
Discussion
It was touch and go on Sunday about whether I would make it to church. My sleep patterns have been less than consistent, with severe insomnia keeping me awake nights, so scheduling anything before noon has been challenging. But I managed to drop off to sleep early on Saturday night,…
Discussion
There was no bell at the cancer center in 2018 when I was first treated. The place was small and crowded. No one who finished treatment rang a bell to mark the end of their infusions. The end of my treatment was recognized with a farewell and best wishes. But…
Discussion
A 55-year-old man with severe lung disease and cold agglutinin disease (CAD) successfully underwent a lung transplant with no CAD-related complications thanks to several preventive strategies, a case study reported. To avoid complications from a drop in body temperature during surgery, which could trigger CAD-related red blood cell destruction,…
Discussion
I gave up. I bought a snack box of 12 little chocolate cake rolls. I have loved them ever since my granddad served them to us grandkids when we were at their house every Tuesday afternoon. The chocolate rolls are filled with a sweet, creamy scrumptiousness and covered with a…
Cold agglutinin disease (CAD) is a rare disorder in which the immune system mistakenly attacks red blood cells, resulting in anemia.
CAD is characterized by autoantibodies, called cold agglutinins, binding to and activating the destruction of red blood cells when exposed to cold temperatures.
Symptoms of CAD include fatigue, Raynaud’s syndrome, joint pain, jaundice or skin discoloration, and heart problems. These symptoms can worsen with more cold exposure.
Get regular updates to your inbox.
